Orexin-A vs Lixisenatide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Lixisenatide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Hypocretin-1 (Orexin-A) | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | 3562 Da | 4858 Da |
| Half-Life | Minutes to <1 hour | 2-4 hours |
| Amino Acids | 33 | 44 |
| Typical Dose | Research-only; no validated human dose | 10-20 mcg daily |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 400 |
| Research Status | Pre-clinical | Approved |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.